Dermata Therapeutics (DRMA) Accounts Payables (2020 - 2026)
Dermata Therapeutics (DRMA) posted quarterly Accounts Payables of $100000.0 for Q1 2026, down 92.83% year-over-year from $1.4 million in Q1 2025, and down 78.3% quarter-over-quarter from $460811.0 in Q4 2025.
Dermata Therapeutics (DRMA) Accounts Payables (2020 - 2026) Analysis & Trends
Dermata Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $100000.0 for Q1 2026.
- In Q1 2026, Accounts Payables fell 92.83% year-over-year to $100000.0; the TTM figure through Mar 2026 stood at $100000.0 (down 92.83% YoY), while the FY2025 annual figure was $460811.0, down 42.97% from the prior year.
- Accounts Payables for Q1 2026 stood at $100000.0, down from $460811.0 in the prior quarter.
- The five-year high for Accounts Payables was $1.4 million in Q1 2025, with the low at $100000.0 in Q1 2026.
- The 5-year median for Accounts Payables is $496702.0 (2022), against an average of $641985.9.
- The sharpest annual moves came in 2024 and 2026: Accounts Payables soared 203.16% in 2024, then slumped 92.83% in 2026.
- Dermata Therapeutics' Accounts Payables stood at $496702.0 in 2022, then jumped by 74.36% to $866028.0 in 2023, then slipped by 6.7% to $808011.0 in 2024, then sank by 42.97% to $460811.0 in 2025, then plunged by 78.3% to $100000.0 in 2026.
- Business Quant data shows DRMA's Accounts Payables at $100000.0 in Q1 2026, $460811.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 35.57 Mn |
| 10 | Dermata Therapeutics | 5.52 Mn | 5.52 Mn | - | 318,331.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 100,000.00 |
| Dec 31, 2025 | 460,811.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 413,687.00 |
| Mar 31, 2025 | 1.40 Mn |
| Dec 31, 2024 | 808,011.00 |
| Sep 30, 2024 | 863,595.00 |
| Jun 30, 2024 | 1.33 Mn |
| Mar 31, 2024 | 822,546.00 |
| Dec 31, 2023 | 866,028.00 |
| Sep 30, 2023 | 474,458.00 |
| Jun 30, 2023 | 437,778.00 |
| Mar 31, 2023 | 492,871.00 |
| Dec 31, 2022 | 496,702.00 |
| Sep 30, 2022 | 483,741.00 |
| Jun 30, 2022 | 608,811.00 |
| Mar 31, 2022 | 662,230.00 |
| Dec 31, 2021 | 515,245.00 |
| Sep 30, 2021 | 769,863.00 |
| Jun 30, 2021 | 881,306.00 |